摘要
目的讨论益心舒片与曲美他嗪协同作用在冠心病心绞痛患者中的临床价值。方法65例冠心病心绞痛患者,随机分为参照组(32例)和研究组(33例)。参照组采用曲美他嗪治疗,研究组采用益心舒片与曲美他嗪联合治疗。比较两组患者心脏相关指标[收缩压(SBP)、舒张压(DBP)、心率(HR)、左心室舒张末期内径(LVEDd)、左心室收缩末期内径(LVESd)、左心室射血分数(LVEF)],不良反应发生情况,治疗前及治疗3个月后血清炎性因子[白细胞介素-27(IL-27)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]水平。结果研究组患者SBP(114.39±9.24)mm Hg(1 mm Hg=0.133 kPa)、DBP(73.34±8.57)mm Hg、HR(73.52±7.96)次/min低于参照组的(126.31±11.58)mm Hg、(83.28±9.49)mm Hg、(82.26±10.05)次/min,LVEDd(50.39±6.45)mm、LVESd(30.99±5.26)mm小于参照组的(56.64±7.34)、(35.63±5.88)mm,LVEF(50.72±7.83)%高于参照组的(44.98±7.26)%,差异有统计学意义((P<0.05)。研究组患者的不良反应发生率为15.152%,低于参照组的46.875%,差异有统计学意义(P<0.05)。治疗3个月后,两组患者的血清CRP、IL-27、TNF-α水平低于本组治疗前,且研究组患者的血清CRP(1.16±0.33)mg/L、IL-27(5.32±1.11)pg/ml、TNF-α(8.59±0.87)pg/ml低于参照组的(1.45±0.54)mg/L、(6.67±1.09)pg/ml、(10.21±0.64)pg/ml,差异有统计学意义(P<0.05)。结论益心舒片与曲美他嗪联合治疗冠心病心绞痛患者疗效确切,安全性良好,为患者带来了实质性的治疗益处和生活质量的提升。
Objective To explore the clinical value of the synergistic effect of Yixinshu tablets and trimetazidine in patients with angina pectoris of coronary heart disease.Methods 65 patients with angina pectoris of coronary heart disease were randomly divided into the reference group(32 cases)and the study group(33 cases).The reference group was treated with trimetazidine,and the study group was treated with Yixinshu tablet combined with trimetazidine.Patients in both groups were compared in terms of heart-related indexes[systolic blood pressure(SBP),diastolic blood pressure(DBP),heart rate(HR),left ventricular end-diastolic diameter(LVEDd),left ventricular end-systolic diameter(LVESd),left ventricular ejection fraction(LVEF)]and the occurrence of adverse reactions,serum levels of inflammatory factors[interleukin-27(IL-27),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)]before and 3 months after treatment.Results The study group had SBP of(114.39±9.24)mm Hg(1 mm Hg=0.133 kPa),DBP of(73.34±8.57)mm Hg,and HR of(73.52±7.96)beats/min,which were lower than(126.31±11.58)mm Hg,(83.28±9.49)mm Hg,and(82.26±10.05)beats/min in the reference group;the study group had LVEDd of(50.39±6.45)mm and LVESd of(30.99±5.26)mm,which were smaller than(56.64±7.34)and(35.63±5.88)mm in the reference group;the study group had a higher LVEF of(50.72±7.83)%than(44.98±7.26)%in the reference group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 15.152%,which was lower than 46.875%in the reference group,and the difference was statistically significant(P<0.05).After 3 months of treatment,the serum levels of CRP,IL-27,and TNF-αin both groups were lower than those before treatment in this group;the study group had serum CRP of(1.16±0.33)mg/L,IL-27 of(5.32±1.11)pg/ml,and TNF-αof(8.59±0.87)pg/ml,which were lower than(1.45±0.54)mg/L,(6.67±1.09)pg/ml,and(10.21±0.64)pg/ml in the reference group;the difference was statistically significant(P<0.05).Conclusion Yixinshu tablet combined with trimetazidine in the treatment of patients with angina pectoris of coronary heart disease is effective and safe,and has brought substantial therapeutic benefits and improved quality of life for patients.
作者
杨锦芳
苏翠珊
YANG Jin-fang;SU Cui-shan(Department of Pharmacy,Jinjiang Hospital,Quanzhou 362200,China)
出处
《中国现代药物应用》
2025年第11期102-105,共4页
Chinese Journal of Modern Drug Application
关键词
益心舒片
曲美他嗪
冠心病
心绞痛
临床价值
Yixinshu tablets
Trimetazidine
Coronary heart disease
Angina pectoris
Clinical value
